Rock Springs Capital Management’s Travere Therapeutics TVTX Stock Holding History

Rock Springs Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.9M	Sell	1,477,954 -732,368	-33%	-$21.9M	2.59%	10
2025 Q4	$84.5M	Buy	2,210,322 +45,549	+2%	+$1.48M	4.33%	4
2025 Q3	$51.7M	Buy	2,164,773 +256,565	+13%	+$4.82M	3.02%	9
2025 Q2	$28.2M	Sell	1,908,208 -1,012,988	-35%	-$16.8M	1.76%	22
2025 Q1	$52.3M	Sell	2,921,196 -2,052,453	-41%	-$41.7M	3%	6
2024 Q4	$86.6M	Buy	4,973,649 +289,173	+6%	+$5.11M	3.3%	7
2024 Q3	$65.5M	Buy	4,684,476 +202,211	+5%	+$2.11M	2.13%	10
2024 Q2	$36.8M	Buy	4,482,265 +1,057,447	+31%	+$7.12M	1.11%	35
2024 Q1	$26.4M	Buy	3,424,818 +653,372	+24%	+$5.51M	0.67%	52
2023 Q4	$24.9M	Buy	2,771,446 +963,704	+53%	+$7.02M	0.61%	48
2023 Q3	$16.2M	Buy	1,807,742 +280,022	+18%	+$3.95M	0.43%	63
2023 Q2	$23.5M	Buy	1,527,720 +251,070	+20%	+$4.57M	0.56%	53
2023 Q1	$28.7M	Buy	1,276,650 +325,000	+34%	+$6.91M	0.69%	48
2022 Q4	$20M	Hold	951,650	–	–	0.48%	57
2022 Q3	$23.4M	Hold	951,650	–	–	0.61%	49
2022 Q2	$23.1M	Hold	951,650	–	–	0.67%	44
2022 Q1	$24.5M	Hold	951,650	–	–	0.62%	54
2021 Q4	$29.5M	Sell	951,650 -545,167	-36%	-$15.4M	0.68%	50
2021 Q3	$36.3M	Buy	1,496,817 +2,653	+0.2%	+$48.7K	0.76%	44
2021 Q2	$21.8M	Buy	1,494,164 +18,600	+1%	+$367K	0.43%	70
2021 Q1	$36.8M	Buy	1,475,564 +454,564	+45%	+$12.6M	0.8%	42
2020 Q4	$27.8M	Sell	1,021,000 -3,261	-0.3%	-$76.1K	0.59%	57
2020 Q3	$18.9M	Hold	1,024,261	–	–	0.48%	68
2020 Q2	$20.9M	Buy	1,024,261 +449,261	+78%	+$7.15M	0.57%	58
2020 Q1	$8.39M	Hold	575,000	–	–	0.35%	80
2019 Q4	$8.16M	Sell	575,000 -375,000	-39%	-$4.79M	0.26%	91
2019 Q3	$11M	Hold	950,000	–	–	0.44%	72
2019 Q2	$19.1M	Buy	950,000 +120,000	+14%	+$2.37M	0.69%	53
2019 Q1	$18.8M	Buy	830,000 +430,000	+108%	+$9.5M	0.72%	49
2018 Q4	$9.05M	Hold	400,000	–	–	0.43%	75
2018 Q3	$11.5M	Hold	400,000	–	–	0.42%	78
2018 Q2	$10.9M	Hold	400,000	–	–	0.42%	79
2018 Q1	$8.94M	Hold	400,000	–	–	0.38%	86
2017 Q4	$8.43M	Hold	400,000	–	–	0.38%	81
2017 Q3	$9.96M	Hold	400,000	–	–	0.46%	72
2017 Q2	$7.76M	Hold	400,000	–	–	0.39%	78
2017 Q1	$7.38M	Sell	400,000 -122,000	-23%	-$2.39M	0.43%	72
2016 Q4	$9.88M	Hold	522,000	–	–	0.66%	50
2016 Q3	$11.7M	Buy	522,000 +600	+0.1%	+$11.4K	0.73%	47
2016 Q2	$9.29M	Hold	521,400	–	–	0.69%	47
2016 Q1	$7.12M	Sell	521,400 -153,600	-23%	-$2.33M	0.6%	54
2015 Q4	$13M	Sell	675,000 -8,900	-1%	-$178K	0.99%	33
2015 Q3	$13.9M	Buy	683,900 +8,900	+1%	+$264K	1.12%	26
2015 Q2	$22.4M	Sell	675,000 -25,000	-4%	-$685K	1.63%	18
2015 Q1	$16.8M	Buy	+700,000	New	+$10.7M	1.57%	20

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rock Springs Capital Management's TVTX Position: Q1 2026 in Review

Rock Springs Capital Management reduced its Travere Therapeutics (TVTX) stake by 33% in Q1 2026, selling an estimated $21.9M and leaving 1,477,954 shares worth $43.9M. The position accounts for 2.59% of the portfolio, ranked #10.

Rock Springs Capital Management first reported a position in TVTX in Q1 2015 and has held it in 45 quarters since. The position peaked at $86.6M in Q4 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Rock Springs Capital Management held 1,477,954 shares of Travere Therapeutics worth $43.9M as of Q1 2026.
Rock Springs Capital Management sold 732,368 Travere Therapeutics shares in Q1 2026, an estimated $21.9M.
Travere Therapeutics made up 2.59% of Rock Springs Capital Management's portfolio in Q1 2026, its #10 holding.
Rock Springs Capital Management first reported a position in Travere Therapeutics in Q1 2015 and has held it in 45 quarters since.
Rock Springs Capital Management's Travere Therapeutics position peaked at $86.6M in Q4 2024.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.